NCT01435213

Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline

Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline - a PET Study in Healthy Human Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Turku · Academic / Other
• Sex: Male
• Age: 20 Years – 40 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to validate \[11C\]ORM-13070 as an alpha2C-adrenoceptor imaging agent for human positron emission tomography (PET) studies of brain alpha2C-adrenoceptor occupancy.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Atipamezole	Administration of a single dose of 5-150 micrograms of atipamezole as an intravenous infusion
DRUG	Atomoxetine	A single dose of 1.2 mg/kg of atomoxetine administered orally
DRUG	Ketamine	A single dose of ketamine (approximately 60 mg) administered as an intravenous infusion
OTHER	Cold pressor test	30-45 min cold pressor test of the foot
DRUG	Insulin	Insulin administered as an intravenous infusion to induce hypoglycemia
DRUG	Placebo	A single dose of placebo (capsules) administered orally

Timeline

• Start date: 2011-09-01
• Primary completion: 2012-01-01
• Completion: 2012-01-01
• First posted: 2011-09-16
• Last updated: 2013-02-18

Locations

2 sites across 1 country: Finland